阿托伐他汀联合曲美他嗪治疗冠心病的临床效果评价

目的 分析阿托伐他汀+曲美他嗪治疗冠心病的临床疗效。方法 选取2016年1月~2017年12月来我院就诊的86例冠心病患者，随机分为对照组和研究组，每组43例。两组患者均接受常规治疗，对照组在此基础上服用盐酸曲美他嗪片，研究组服用阿托伐他汀钙片+盐酸曲美他嗪片，观察两组患者治疗总有效率、血脂指标、常规指标及不良反应的发生情况。结果 研究组治疗总有效率为93.02%，高于对照组的76.74%，差异具有统计学意义（P＜0.05）。研究组血脂指标及常规指标优于对照组，差异有统计学意义（P＜0.05）。研究组不良反应发生率为4.65%，低于对照组的18.60%，差异有统计学意义（P＜0.05）。结论 阿托伐他汀联合曲美他嗪治疗冠心病疗效显著，安全性高，值得推广应用。

Clinical Evaluation of Atto Vastatin Combined with Trimetazidine in the Treatment of Coronary Atherosclerotic Heart Disease

Abstract:Objective To analyze the clinical efficacy of Atto vastatin combined with trimetazidine in the treatment of coronary atherosclerotic heart disease.Methods 86 patients with coronary atherosclerotic heart disease from January 2016 to December 2017 were randomly divided into control group(n=43)and study group(n=43).Patients in both groups received routine treatment,the control group took trimetazidine hydrochloride tablets on this basis,and the study group took Atto vastatin calcium+trimetazidine hydrochloride tablets.The total effective rate and blood lipid index of the two groups were observed as well as routine indicators and adverse reactions.Results The total effective rate of the study group was 93.02%,which was higher than that of the control group 76.74%,the difference was statistically significant(P<0.05).The blood lipid index and routine index in the study group were better than those in the control group,and the difference was statistically significant(P<0.05).The incidence of adverse reactions in the study group was 4.65%,which was significantly lower than that in the control group 18.60%,the difference was statistically significant(P<0.05).Conclusion Atto vastatin combined with trimetazidine is effective and safe in the treatment of coronary atherosclerotic heart disease.